BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38330179)

  • 1. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
    van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
    Blood Adv; 2024 May; 8(10):2433-2441. PubMed ID: 38330179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
    Glenthøj A; van Beers EJ; Al-Samkari H; Viprakasit V; Kuo KHM; Galactéros F; Chonat S; Porter J; Zagadailov E; Xu R; Oluyadi A; Hawkins P; Gheuens S; Beynon V; Barcellini W;
    Lancet Haematol; 2022 Oct; 9(10):e724-e732. PubMed ID: 35988546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
    Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
    N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
    Grace RF; Rose C; Layton DM; Galactéros F; Barcellini W; Morton DH; van Beers EJ; Yaish H; Ravindranath Y; Kuo KHM; Sheth S; Kwiatkowski JL; Barbier AJ; Bodie S; Silver B; Hua L; Kung C; Hawkins P; Jouvin MH; Bowden C; Glader B
    N Engl J Med; 2019 Sep; 381(10):933-944. PubMed ID: 31483964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults.
    Zhuang-Yan A; Shirley M
    Drugs; 2023 Nov; 83(17):1613-1620. PubMed ID: 37991635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
    Wills J; Horenstein M; Kim A; Silva MA; Dima L
    Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
    Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios.
    Mojzikova R; Koralkova P; Holub D; Zidova Z; Pospisilova D; Cermak J; Striezencova Laluhova Z; Indrak K; Sukova M; Partschova M; Kucerova J; Horvathova M; Divoky V
    Br J Haematol; 2014 May; 165(4):556-63. PubMed ID: 24533562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment.
    Al-Samkari H; Grace RF; Glenthøj A; Andres O; Barcellini W; Galacteros F; Kuo KHM; Layton DM; Morado M; Viprakasit V; Tai F; Urbstonaitis R; Morales J; McGee B; Beers EJV
    Haematologica; 2024 Mar; 109(3):963-967. PubMed ID: 37731369
    [No Abstract]   [Full Text] [Related]  

  • 10. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
    Shah AJ; Schwartz JD; Segovia JC
    N Engl J Med; 2022 Jun; 386(26):2538-2539. PubMed ID: 35767453
    [No Abstract]   [Full Text] [Related]  

  • 11. An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
    Song AB; Al-Samkari H
    Expert Rev Hematol; 2022 Oct; 15(10):875-885. PubMed ID: 36124781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. Reply.
    Al-Samkari H; Beynon V; van Beers EJ
    N Engl J Med; 2022 Jun; 386(26):2539. PubMed ID: 35767454
    [No Abstract]   [Full Text] [Related]  

  • 13. Mitapivat for sickle cell disease and thalassemia.
    Pilo F; Angelucci E
    Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.
    Grace RF; Bianchi P; van Beers EJ; Eber SW; Glader B; Yaish HM; Despotovic JM; Rothman JA; Sharma M; McNaull MM; Fermo E; Lezon-Geyda K; Morton DH; Neufeld EJ; Chonat S; Kollmar N; Knoll CM; Kuo K; Kwiatkowski JL; Pospíšilová D; Pastore YD; Thompson AA; Newburger PE; Ravindranath Y; Wang WC; Wlodarski MW; Wang H; Holzhauer S; Breakey VR; Kunz J; Sheth S; Rose MJ; Bradeen HA; Neu N; Guo D; Al-Sayegh H; London WB; Gallagher PG; Zanella A; Barcellini W
    Blood; 2018 May; 131(20):2183-2192. PubMed ID: 29549173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitapivat for treatment of pyruvate kinase deficiency.
    Costa FF
    Lancet Haematol; 2022 Oct; 9(10):e708-e709. PubMed ID: 35988547
    [No Abstract]   [Full Text] [Related]  

  • 16. Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial.
    Andrae DA; Grace RF; Jewett A; Foster B; Klaassen RJ; Salek S; Li J; Tai F; Boscoe AN; Zagadailov E
    J Patient Rep Outcomes; 2023 Nov; 7(1):112. PubMed ID: 37943362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyruvate kinase activators for treatment of pyruvate kinase deficiency.
    Grace RF
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):97-106. PubMed ID: 38066940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidities and complications in adults with pyruvate kinase deficiency.
    Boscoe AN; Yan Y; Hedgeman E; van Beers EJ; Al-Samkari H; Barcellini W; Eber SW; Glader B; Yaish HM; Chonat S; Sharma M; Kuo KHM; Neufeld EJ; Wang H; Verhovsek M; Sheth S; Grace RF
    Eur J Haematol; 2021 Apr; 106(4):484-492. PubMed ID: 33370479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency.
    Kuo KHM; Grace RF; van Beers EJ; Barcellini W; Glenthøj A; Holzhauer S; Beynon V; Morris S; Li J; Zagadailov E; Patel P; Al-Samkari H
    Am J Hematol; 2024 Jul; 99(7):1415-1419. PubMed ID: 38712615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates and advances in pyruvate kinase deficiency.
    Luke N; Hillier K; Al-Samkari H; Grace RF
    Trends Mol Med; 2023 May; 29(5):406-418. PubMed ID: 36935283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.